ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,022.26
      -0.27%
      US Tech 100
      16,880.00
      -0.61%
      Dow Jones
      37,919.88
      0.27%
      Brent Oil
      84.155
      -2.03%
      Bitcoin
      57,080.77
      -5.81%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Marker Therapeutics Inc (MRKR)

      7. Marker Therapeutics Inc (MRKR) News

      MRKR

      Marker Therapeutics (MRKR)

      Marker Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MRKR
      DateTimeSourceHeadlineSymbolCompany
      04/08/20247:00AMGlobeNewswire Inc.Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies NASDAQ:MRKRMarker Therapeutics Inc
      03/25/20245:45PMGlobeNewswire Inc.Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsNASDAQ:MRKRMarker Therapeutics Inc
      03/22/202412:30PMGlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:MRKRMarker Therapeutics Inc
      03/01/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      02/26/20247:58AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      01/22/20247:30AMGlobeNewswire Inc.Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601NASDAQ:MRKRMarker Therapeutics Inc
      01/08/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      01/08/20248:24AMGlobeNewswire Inc.Marker Therapeutics Announces Clinical Program Updates and Pipeline PrioritizationNASDAQ:MRKRMarker Therapeutics Inc
      12/21/202311:00AMGlobeNewswire Inc.Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”NASDAQ:MRKRMarker Therapeutics Inc
      12/11/20237:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      12/11/20237:00AMGlobeNewswire Inc.Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
      11/20/20234:37PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      11/09/20235:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      11/09/20235:00PMGlobeNewswire Inc.Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
      11/09/20234:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
      09/11/20237:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      09/11/20237:00AMGlobeNewswire Inc.Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
      08/30/20238:00AMGlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MRKRMarker Therapeutics Inc
      08/14/20234:37PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      08/14/20234:30PMGlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:MRKRMarker Therapeutics Inc
      08/14/20234:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
      08/07/20237:22AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      08/07/20237:00AMGlobeNewswire Inc.Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf ProgramNASDAQ:MRKRMarker Therapeutics Inc
      07/26/20237:00AMGlobeNewswire Inc.Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023NASDAQ:MRKRMarker Therapeutics Inc
      07/10/20237:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      07/10/20237:00AMGlobeNewswire Inc.European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML PatientsNASDAQ:MRKRMarker Therapeutics Inc
      07/05/20234:22PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRKRMarker Therapeutics Inc
      07/03/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      06/30/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
      06/26/20237:15AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MRKRMarker Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:MRKR